SCHEMBL4222611

SCHEMBL4222611

CNc1cccc(-c2ccc(C=C(F)C(=O)O)cc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.44
MGLL Q99685 1/20 0.43
PTGS2 P35354 2/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 2/20 0.40
TRIM24 O15164 1/20 0.39
TRIM33 Q9UPN9 1/20 0.39
CNR1 P21554 4/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
NFKB1 P19838 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PNPLA2 Q96AD5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4222609 1.00 TP53 (0.44) TP53MGLLPTGS2MEN1KMT2A
SCHEMBL4225896 0.84 AKR1C3 (0.51) TP53MGLLPTGS2MEN1KMT2A
SCHEMBL4225892 0.84 AKR1C3 (0.51) TP53MGLLPTGS2MEN1KMT2A
SCHEMBL4213905 0.82 DHODH (0.52) MGLLMEN1KMT2AGAAMAPT
SCHEMBL4213907 0.82 DHODH (0.52) MGLLMEN1KMT2AGAAMAPT
SCHEMBL4220316 0.82 TP53 (0.43) TP53MGLLPTGS2MEN1KMT2A
SCHEMBL4220313 0.82 TP53 (0.43) TP53MGLLPTGS2MEN1KMT2A
SCHEMBL4220307 0.82 TP53 (0.43) TP53MGLLPTGS2MEN1KMT2A
SCHEMBL2085567 0.81 TBXAS1 (0.46) TP53MGLLPTGS2MEN1KMT2A
SCHEMBL4221575 0.81 TBXAS1 (0.46) TP53MGLLPTGS2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US disclosed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS PPARG, PPARD, PPARA TP53 436/4885MGLL 318/4885PTGS2 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.